Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743731 | 0.88 | AKR1B1 (0.59) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL9985451 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAKMT2AMEN1TP53 | |
| SCHEMBL5252336 | 0.84 | KMT2A (0.60) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL7638563 | 0.84 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAKMT2AMEN1TP53 | |
| SCHEMBL29943508 | 0.84 | KMT2A (0.60) | SMN1; SMN2LMNAKMT2AMEN1MAPT | |
| SCHEMBL28724963 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAKMT2AMEN1TP53 | |
| SCHEMBL28158406 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2KMT2AALDH1A1HPGDPOLB | |
| SCHEMBL9729592 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAKMT2ATP53MAPT | |
| SCHEMBL2373994 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2KMT2AALDH1A1HPGDKDM4E | |
| SCHEMBL28031637 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAKMT2AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| EP-4452964-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118339153-A | Heteroaromatic compounds for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-116804004-A | Compounds as DHODH inhibitors | 南京征祥医药有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230271943-A1 | COMPOUNDS AS DHODH INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271943-A1 | COMPOUNDS AS DHODH INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-116457343-A | Compounds as DHODH inhibitors | 南京征祥医药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023117681-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022012548-A1 | COMPOUNDS AS DHODH INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | WO | disclosed |
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-8143280-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | disclosed |
| CN-101808992-A | 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives | HOFFMANN LA ROCHE | 2010-08-18 | — | — | CN | disclosed |
| EP-2205562-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| WO-2003076403-A1 | 1,2-DISUBSTITUDED-6-OXO-3-PHENYL-PIPERIDINE-3-CARBOXAMIDES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| US-20030171588-A1 | 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-09-11 | — | — | US | disclosed |
| CN-1008055-B | PESTICIDE COMPOSITION WITH ACRYLIC DERIVS. AS ACTIVE COMPONENT AND PROCESS FOR PREPARING SAME, AND USE THEREOF | ICI PLC (GB) | 1990-05-23 | — | — | CN | disclosed |
| CN-85108235-A | The preparation of sterilant | — | 1986-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171588-A1 | 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof | BRD4, BICRA, HDAC6 | SMN1; SMN2 1499/4885LMNA 3593/4885KMT2A 202/4885 |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | SMN1; SMN2 4332/4885LMNA 2852/4885KMT2A 2424/4885 |
| US-20230271943-A1 | COMPOUNDS AS DHODH INHIBITORS | DHODH, DLD, DHRS9 | SMN1; SMN2 3538/4885LMNA 3421/4885KMT2A 2940/4885 |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | SMN1; SMN2 4680/4885LMNA 2031/4885KMT2A 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.